BioAge Labs, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

BIOA$5.78+1.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity

Unaudited Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share information)

Accumulated
Additional · Other · Total
Common stock · Paid-In · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance, December 31, 2025	37,386,908	$—	$605,189	$278	$(333,416)	$272,051
Underwritten stock offering, net of underwriting discounts and commissions, and offering expenses	6,782,050	—	123,557	—	—	123,557
Stock option exercises	217,827	—	1,715	—	—	1,715
Stock-based compensation expense	—	—	4,256	—	—	4,256
Unrealized loss on marketable securities	—	—	—	(178)	—	(178)
Foreign currency translation adjustment	—	—	—	(27)	—	(27)
Net loss	—	—	—	—	(22,253)	(22,253)
Balance, March 31, 2026	44,386,785	$—	$734,717	$73	$(355,669)	$379,121
Issuance of common shares under at-the-market sales agreement, net of placement agent fee and offering costs	1,000,000	—	15,637	—	—	15,637
Stock option exercises	390,117	—	2,534	—	—	2,534
Stock-based compensation expense	—	—	4,269	—	—	4,269
Unrealized loss on marketable securities	—	—	—	(547)	—	(547)
Foreign currency translation adjustment	—	—	—	(4)	—	(4)
Net loss	—	—	—	—	(26,097)	(26,097)
Balance, June 30, 2026	45,776,902	$—	$757,157	$(478)	$(381,766)	$374,913
Issuance of common stock under employee stock purchase plan	16,318	—	98	—	—	98
Stock option exercises	157,858	—	984	—	—	984
Stock-based compensation expense	—	—	4,644	—	—	4,644
Unrealized loss on marketable securities	—	—	—	(724)	—	(724)
Foreign currency translation adjustment	—	—	—	35	—	35
Net loss	—	—	—	—	(33,504)	(33,504)
Balance, September 30, 2026	45,951,078	$—	$762,883	$(1,167)	$(415,270)	$346,446

Accumulated
Additional · Other · Total
Common stock · Paid-In · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	Income	Deficit	Equity
Balance, December 31, 2024	35,850,037	$—	$575,693	$245	$(252,811)	$323,127
Stock-based compensation expense	—	—	2,949	—	—	2,949
Unrealized gain on marketable securities	—	—	—	29	—	29
Foreign currency translation adjustment	—	—	—	(10)	—	(10)
Net loss	—	—	—	—	(12,928)	(12,928)
Balance, March 31, 2025	35,850,037	$—	$578,642	$264	$(265,739)	$313,167
Stock-based compensation expense	—	—	3,229	—	—	3,229
Foreign currency translation adjustment	—	—	—	(52)	—	(52)
Net loss	—	—	—	—	(21,563)	(21,563)
Balance, June 30, 2025	35,850,037	$—	$581,871	$212	$(287,302)	$294,781
Stock-based compensation expense	—	—	2,791	—	—	2,791
Unrealized gain on marketable securities	—	—	—	73	—	73
Foreign currency translation adjustment	—	—	—	(10)	—	(10)
Net loss	—	—	—	—	(20,171)	(20,171)
Balance, September 30, 2025	35,850,037	$—	$584,662	$275	$(307,473)	$277,464

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.